{"nctId":"NCT01641640","briefTitle":"Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection","startDateStruct":{"date":"2012-06"},"conditions":["Chronic Hepatitis C"],"count":328,"armGroups":[{"label":"Sofosbuvir+PEG+RBV","type":"EXPERIMENTAL","interventionNames":["Drug: Sofosbuvir","Drug: RBV","Drug: PEG"]}],"interventions":[{"name":"Sofosbuvir","otherNames":["Sovaldi®","GS-7977","PSI-7977"]},{"name":"RBV","otherNames":["Ribasphere®"]},{"name":"PEG","otherNames":["PEGASYS®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infection with HCV genotype 1, 4, 5, or 6\n* Cirrhosis determination\n* Subject met the following classifications:\n\n  * Treatment-naive\n  * Screening laboratory values within defined thresholds\n  * Not treated with any investigational drug or device within 30 days of screening\n* Use of highly effective contraception methods if female of childbearing potential or sexually active male\n\nExclusion Criteria:\n\n* Prior exposure to an direct-acting antiviral targeting the HCV nonstructural protein (NS)5B polymerase\n* Pregnant or nursing female, or male with pregnant female partner\n* Current or prior history of clinical hepatic decompensation\n* History of clinically-significant illness or any other major medical disorder that may have interfered with subject treatment, assessment, or compliance with the protocol\n* Excessive alcohol ingestion or significant drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Sustained Virologic Response (SVR)12","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) 12 weeks after cessation of therapy.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug","description":"The number of participants experiencing adverse events leading to permanent discontinuation of study drug was summarized. Adverse events may or may not have been related to study treatment. Participants discontinuing study drug were permitted to remain on the study for further assessments.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SVR4","description":"SVR4 was defined as HCV RNA \\< LLOQ 4 weeks after cessation of therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving SVR24","description":"SVR24 was defined as HCV RNA \\< LLOQ 24 weeks after cessation of therapy","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Breakthrough","description":"Viral breakthrough was defined as HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while receiving treatment, confirmed with 2 consecutive values (second confirmation value could be posttreatment), or last available on-treatment measurement with no subsequent follow-up values.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Viral Relapse","description":"Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at end of treatment, confirmed with 2 consecutive values or last available posttreatment measurement.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":327},"commonTop":["Fatigue","Headache","Nausea","Insomnia","Anaemia"]}}}